Medicine and Dentistry
Patient
100%
Ipilimumab
45%
Nivolumab
31%
Combination Therapy
27%
Mucosal Melanoma
22%
Antibody
13%
Disease Exacerbation
13%
Progression Free Survival
13%
Deterioration
9%
Nodular Melanoma
9%
CTLA-4
9%
Diseases
4%
Toxicity
4%
Alanine Aminotransferase
4%
Overall Survival
4%
Colitis
4%
Antibody Therapy
4%
Pembrolizumab
4%
Survival
4%
Nursing and Health Professions
Ipilimumab
45%
Nivolumab
31%
Combination Therapy
27%
Mucosal Melanoma
22%
Death
18%
Inpatient
18%
Antibody
13%
Disease Exacerbation
13%
Progression Free Survival
13%
Deterioration
9%
Tumor Volume
9%
Melanoma
9%
Cytotoxic T Lymphocyte Antigen 4
9%
Diseases
4%
Overall Survival
4%
Hospital
4%
Toxicity
4%
Survival
4%
Alanine Aminotransferase
4%
Colitis
4%
Pembrolizumab
4%
Pharmacology, Toxicology and Pharmaceutical Science
Ipilimumab
45%
Nivolumab
31%
Mucosal Melanoma
22%
Death
18%
Disease Exacerbation
13%
Antibody
13%
Progression Free Survival
13%
Deterioration
9%
Melanoma
9%
Cytotoxic T Lymphocyte Antigen 4
9%
Toxicity
4%
Diseases
4%
Alanine Aminotransferase
4%
Overall Survival
4%
Colitis
4%
Pembrolizumab
4%
Survival
4%
Immunology and Microbiology
Ipilimumab
45%
Nivolumab
31%
Monospecific Antibody
18%
Progression Free Survival
13%
CTLA-4
9%
Tumor Volume
9%
Overall Survival
4%
Colitis
4%
Pembrolizumab
4%
Survival
4%
Neuroscience
Ipilimumab
45%
Nivolumab
31%
Antibodies
18%
Cytotoxic T Lymphocyte Antigen 4
9%
Alanine Aminotransferase
4%
Lambrolizumab
4%